PYLARIFY AI™ is a deep learning application that enables accurate, efficient, and reproducible quantification of PSMA PET/CT scans.


ADVANCED PSMA ASSESSMENT

Advanced PSMA Assessment

Pylarify AI

TM

Learn More

PYLARIFY AI™ is the only FDA-cleared medical device to offer standardized quantitative and accurate reporting of PSMA PET/CT images. Standardized reporting of PSMA assessments can improve the management of prostate cancer patients, including the accurate quantification of disease burden with increased reproducibility on a patient level.

1

2,3

 1,2

References

1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.

2. Nickols N, Anand A, Johnsson K, et al. aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer. J Nucl Med. 2021.

3. Johnsson, K., Brynolfsson, J., Sahlstedt, H. et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging 49, 1041–1051 (2022). https://doi.org/10.1007/s00259-021-05497-8


Terms of use & privacy policy

©2022 SYNTERMED INC. - ALL RIGHTS RESERVED. | FOR PERMISSION, EMAIL 

Emory Toolbox is a trademark of Emory University.    AdreView, Xeleris, DaTscan, Vizamyl and GE are trademarks of General Electric Company.
Amyvid is a trademark of Eli Lilly and Company.    NeuraCeq is a trademark of Piramal Imaging.    ImageGuide is a trademark of the American Society of Nuclear Cardiology.   
PYLARIFY AI is a Trademark of Lantheus Holdings, Inc.

Syntermed medical devices have received FDA (Quality System Records/Pre-Market Notfication) 510(k) clearance and European Union (ISO 13485:2016 FM 670241/CE Mark 696491) regulations. See eIFU for ECTb and NeuroQ.

Syntermed, Inc.
333 Sandy Springs Circle NE, Suite 107, Atlanta, GA 30328

TEL (888) 263-4446 | FAX (888) 216-7511

Privacy Notice    

HIPAA     

MSA